Rosalind Advisors Inc's Q1 2025 13F: 7 new positions, 4 exits
Form 13F-HR for the quarter ended Mar 31, 2025 · filed May 14, 2025 · 31 reported positions · accession 0001622627-25-000027
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Exited | CHIMERIX INC (CMRX) | 5.7% | — | −5.7 pts | −3.05M sh | −100% |
| New | IDEAYA BIOSCIENCES INC (IDYA) | — | 5.6% | +5.6 pts | +700K sh | new |
| Increased | VERASTEM INC (VSTM) | 2.5% | 7.8% | +5.3 pts | +1.74M sh | +194% |
| New | VIRIDIAN THERAPEUTICS INC (VRDN) | — | 3.9% | +3.9 pts | +595K sh | new |
| Increased | REPLIMUNE GROUP INC (REPL) | 1.7% | 4.0% | +2.3 pts | +590K sh | +227% |
| Reduced | OPTINOSE INC (OPTN) | 3.2% | 1.1% | −2.0 pts | −621K sh | −71% |
| New | NUVATION BIO INC (NUVB) | — | 2.1% | +2.1 pts | +2.45M sh | new |
| New | PHARVARIS N V (PHVS) | — | 1.7% | +1.7 pts | +224K sh | new |
| Reduced | XERIS BIOPHARMA HOLDINGS INC (XERS) | 5.7% | 6.7% | +1.0 pts | −609K sh | −20% |
| Increased | FENNEC PHARMACEUTICALS INC (FENC) | 4.3% | 5.3% | +1.0 pts | +523K sh | +42% |
| Reduced | VERONA PHARMA PLC (VRNA) | 3.8% | 3.1% | −0.7 pts | −50,000 sh | −33% |
| Reduced | TREVI THERAPEUTICS INC (TRVI) | 2.4% | 1.9% | −0.5 pts | −450K sh | −42% |
| Increased | DELCATH SYS INC (DCTH) | 17.2% | 14.1% | −3.1 pts | +250K sh | +9% |
| New | MIND MEDICINE MINDMED INC (MNMD) | — | 1.2% | +1.2 pts | +420K sh | new |
| Reduced | MEDIWOUND LTD (MDWD) | 6.0% | 3.8% | −2.2 pts | −121K sh | −19% |
| New | COGENT BIOSCIENCES INC (COGT) | — | 0.7% | +0.7 pts | +248K sh | new |
| Reduced | MYOMO INC (MYO) | 10.4% | 6.3% | −4.1 pts | −295K sh | −10% |
| Exited | CASSAVA SCIENCES INC (SAVA) | 0.5% | — | −0.5 pts | −417K sh | −100% |
| Increased | UROGEN PHARMA LTD (URGN) | 5.0% | 5.1% | +0.1 pts | +80,000 sh | +9% |
| Reduced | ALPHA COGNITION INC (ACOG) | 0.8% | 0.3% | −0.5 pts | −148K sh | −59% |
| Increased | TALPHERA INC (TLPH) | 0.2% | 0.5% | +0.3 pts | +1.39M sh | +226% |
| New | KURA ONCOLOGY INC (KURA) | — | 0.3% | +0.3 pts | +100K sh | new |
| Increased | OCULAR THERAPEUTIX INC (OCUL) | 5.2% | 4.4% | −0.8 pts | +90,000 sh | +8% |
| Reduced | INSPIREMD INC (NSPR) | 3.5% | 3.0% | −0.6 pts | −221K sh | −9% |
| Increased | COMPASS PATHWAYS PLC (CMPS) | 1.4% | 1.1% | −0.3 pts | +116K sh | +16% |
| Exited | OWLET INC (OWLT) | 0.1% | — | −0.1 pts | −49,441 sh | −100% |
| Reduced | BIOFRONTERA INC (BFRI) | 0.5% | 0.3% | −0.2 pts | −168K sh | −21% |
| Exited | RELMADA THERAPEUTICS INC (RLMD) | 0.0% | — | 0.0 pts | −100K sh | −100% |
| Increased | ABEONA THERAPEUTICS INC (ABEO) | 5.4% | 4.2% | −1.2 pts | +427 sh | 0% |
| Reduced | KIORA PHARMACEUTICALS INC (KPRX) | 0.4% | 0.4% | −0.1 pts | −496 sh | 0% |
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
Top 10 positions — 63.5% of the equity book
Changes in the top 10 this quarter: VSTM entered · IDYA entered · REPL entered · MDWD left · CMRX left · SVRA left
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | DELCATH SYS INC (DCTH) | 17.2% | 14.1% | |
| 2 | VERASTEM INC (VSTM) | 2.5% | 7.8% | Entered the top 10 |
| 3 | XERIS BIOPHARMA HOLDINGS INC (XERS) | 5.7% | 6.7% | |
| 4 | MYOMO INC (MYO) | 10.4% | 6.3% | |
| 5 | IDEAYA BIOSCIENCES INC (IDYA) | 0.0% | 5.6% | Entered the top 10 |
| 6 | FENNEC PHARMACEUTICALS INC (FENC) | 4.3% | 5.3% | |
| 7 | UROGEN PHARMA LTD (URGN) | 5.0% | 5.1% | |
| 8 | OCULAR THERAPEUTIX INC (OCUL) | 5.2% | 4.4% | |
| 9 | ABEONA THERAPEUTICS INC (ABEO) | 5.4% | 4.2% | |
| 10 | REPLIMUNE GROUP INC (REPL) | 1.7% | 4.0% | Entered the top 10 |
| — | MEDIWOUND LTD (MDWD) | 6.0% | 3.8% | Left the top 10 |
| — | CHIMERIX INC (CMRX) | 5.7% | 0.0% | Left the top 10 |
| — | SAVARA INC (SVRA) | 4.4% | 3.6% | Left the top 10 |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).
Option positions (puts and calls)
Reported separately from the positions above. The value a 13F reports for an option is that of the underlying shares, not the option itself.
| Activity | Security | Type | Shares before | Shares now | Reported value |
|---|---|---|---|---|---|
| Exited | CASSAVA SCIENCES INC (SAVA) | Put | 417K | 0 | $0 |
| Exited | BIOMEA FUSION INC (BMEA) | Put | 911K | 0 | $0 |
| Exited | CORMEDIX INC (CRMD) | Call | 184K | 0 | $0 |
| Exited | EDGEWISE THERAPEUTICS INC (EWTX) | Put | 238K | 0 | $0 |
| Exited | ISHARES TR (NYC) | Put | 200K | 0 | $0 |
| Exited | SPDR SER TR (BIL) | Put | 800K | 0 | $0 |
| Exited | NEUMORA THERAPEUTICS INC. (NMRA) | Put | 137K | 0 | $0 |
| Exited | RELMADA THERAPEUTICS INC (RLMD) | Put | 100K | 0 | $0 |
| Exited | SPDR SER TR (BIL) | Call | 1.4M | 0 | $0 |
| Reduced | INVESCO QQQ TR (QQQ) | Put | 100K | 50,000 | $374K |
| Reduced | CANDEL THERAPEUTICS INC (CADL) | Put | 263K | 15,800 | $3.57K |